source
- J&J and Contineum's oral M1 inhibitor fails second mid-stage depression trialContineum Therapeutics and Johnson & Johnson reported that their oral M1 receptor inhibitor, known as PIPE-307 or JNJ-5120, did not meet its primary endpoints in a Phase II study for major depressi…
- Experts urge FDA to require credentials for psychedelic therapy providersAt a recent public hearing, mental health experts called on the FDA to adopt safety measures as it pushes to speed up psychedelic therapy development. The experts specifically recommended that pro…